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Background: Glucagon-like Peptide-1 (GLP-1) is essential for normal glucose tolerance and it exerts anti-apoptotic and cytoprotective actions. We 
have previously shown that Exenatide, a GLP-1 receptor (GLP-1r) agonist used for the treatment of Type 2 diabetes, reduces infarct size and improves 
systolic function in a pig model of ischemia-reperfusion. However, the effects of Exenatide on diastolic function after myocardial infarction (MI) 
remain unclear.
Methods: Acute MI was induced in Yorkshire pigs by balloon occlusion of the proximal LAD for 60 minutes, followed by reperfusion. Animals were 
randomly assigned to receive either Exenatide (10 μg i.v.; n=6) 10 minutes prior to reperfusion and then twice daily for the next 3 days, or saline 
for controls (n=6). Magnetic resonance imaging (MRI) and echocardiography were performed at 1 month post MI. For MRI assessment of diastolic 
function, LV volume-time filling curve was generated. First peak filling rate (PFR), time to PFR (nTPFR, normalized by stroke volume) and first filling 
volume were analyzed. Tissue was collected at 1 month for histological analyses.
Results: Exenatide pigs showed higher PFR (0.3 ± 0.04 vs. 0.2 ± 0.1 mL/s, p < 0.05), shorter nTPFR (9.6 ± 0.9 vs. 7.4 ± 1.9, p < 0.05) and larger 
first filling volume (33.9 ± 5.1 vs. 24.31 ± 4.09mL, p < 0.05). These MRI findings were supported by our echocardiography results; Exenatide-
treated animals showed greater color M-mode propagation velocities (32.9 ± 2.5 vs. 25.7 ± 6.05cm/s, p < 0.05) and improved myocardial 
performance index (0.53 ± 0.03 vs. 0.69 ± 0.1, p < 0.05), compared to placebo. There were no differences in LV end-diastolic pressure or pulmonary 
capillary wedge pressure between Exenatide treatment and placebo. There was a significant inverse correlation between first filling volume and 
histomorphometric measures of cardiomyocyte hypertrophy (r=-0.72, p<0.05) for both myocyte cross-sectional area and perimeter.
Conclusions: GLP-1r activation by Exenatide immediately prior to reperfusion significantly reduced diastolic dysfunction at 1 month after MI. Our 
observations underscore the therapeutic potential of GLP-1 system in MI patients. Further studies in humans are warranted.
